Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line

Pin Ren, Christian Tiede, Sean W. Fanning, Thomas Adams, Valerie Speirs, Erik R. Nelson, Changfeng Cheng, Terry W. Moore, Geoffrey L. Greene, Darren Tomlinson, Paul R. Selvin

Research output: Contribution to journalArticlepeer-review

Abstract

Mutations of the intracellular estrogen receptor alpha (ERα) is implicated in 70% of breast cancers. Therefore, it is of considerable interest to image various mutants (L536S, Y537S, D538G) in living cancer cell lines, particularly as a function of various anticancer drugs. We therefore developed a small (13 kDa) Affimer, which, after fluorescent labeling, is able to efficiently label ERα by traveling through temporary pores in the cell membrane, created by the toxin streptolysin O. The Affimer, selected by a phage display, predominantly labels the Y537S mutant and can tell the difference between L536S and D538G mutants. The vast majority of Affimer-ERαY537S is in the nucleus and is capable of an efficient, unrestricted navigation to its target DNA sequence, as visualized by single-molecule fluorescence. The Affimer can also differentiate the effect of selective estrogen receptor modulators. More generally, this is an example of a small binding reagent—an Affimer protein—that can be inserted into living cells with minimal perturbation and high efficiency, to image an endogenous protein.

Original languageEnglish (US)
JournalBiophysical journal
DOIs
StatePublished - Oct 4 2022

ASJC Scopus subject areas

  • Biophysics

Fingerprint

Dive into the research topics of 'Labeling of a mutant estrogen receptor with an Affimer in a breast cancer cell line'. Together they form a unique fingerprint.

Cite this